Plecanatide
FDA-approved GC-C medicines that activate their target pathway (Trulance) for CIC and IBS-C.
Ref $ —reference only
PlecanatideFDA-approvedWhat it's for
FDA-approved GC-C medicines that activate their target pathway (Trulance) for CIC and IBS-C.
What it's for
Plecanatide is an analog of uroguanylin that activates intestinal guanylate cyclase-C. It treats chronic idiopathic constipation and IBS with constipation in adults.
What it does for the body
It treats chronic idiopathic constipation and IBS with constipation in adults. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Similar to linaclotide: GC-C → cGMP (a messenger that helps blood vessels relax) → chloride/bicarbonate secretion → improved stool frequency; also gently adjusts visceral sensation pathways. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Plecanatide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Plecanatide — FDA.gov search
- ClinicalTrials.gov search: Plecanatide — U.S. clinical trials registry
- Drugs@FDA search: Plecanatide — FDA drug database (if approved)
- PubMed search: Plecanatide — NCBI PubMed
- PubMed Central search: Plecanatide — NCBI PMC
Reference
No ref on file.